Literature DB >> 3485890

Biochemical markers of bone turnover in rheumatoid arthritis. Relation to anti-inflammatory treatment, sex, and menopause.

O S Als, B J Riis, A Gotfredsen, C Christiansen, L J Deftos.   

Abstract

Bone turnover was determined in 125 patients with rheumatoid arthritis (RA). Bone Gla protein (BGP) and alkaline phosphatase (AP) were used as markers of bone formation. Fasting urinary calcium relative to creatinine (FU Ca/Cr) and fasting urinary hydroxyproline relative to creatinine (FU Hpr/Cr) were used as markers of bone resorption. These variables were compared to the values of two groups of normal controls in order to elucidate the pathophysiology of the osteopenia occurring in patients with RA. When the patients were divided into groups according to treatment (gold salts, penicillamine, or glucocorticoids), serum AP was highly significantly increased in all three groups, whereas serum BGP was below the normal mean. FU Ca/Cr and FU Hpr/Cr were moderately decreased in the groups treated with gold salts or penicillamine, but increased in the glucocorticoid-treated group. When divided according to sex and menopausal state and glucocorticoid treatment versus non-glucocorticoid treatment, there was a balance between bone formation and bone resorption parameters in all groups, except glucocorticoid-treated men and premenopausal women who had increased values of bone resorption parameters.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485890

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  10 in total

Review 1.  Bone metabolism in patients with rheumatoid arthritis.

Authors:  J W Bijlsma
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

2.  Osteocalcin and bone mineral content in rheumatoid arthritis.

Authors:  A Peretz; J P Praet; S Rozenberg; D Bosson; J P Famaey; P Bourdoux
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

3.  Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy.

Authors:  A Conti; A Sartorio; S Ferrero; S Ferrario; B Ambrosi
Journal:  J Endocrinol Invest       Date:  1996-02       Impact factor: 4.256

Review 4.  Menopause and Rheumatic Disease.

Authors:  Mitali Talsania; Robert Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2017-05       Impact factor: 2.670

5.  Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis.

Authors:  H Kröger; J Risteli; L Risteli; I Penttilä; E Alhava
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

6.  Biomarks in secondary osteoporosis.

Authors:  A Aroso Dias; A Lopes Vaz; M Hargreaves; C Afonso; D Araújø; T Bravo
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

7.  Bone turnover in non-steroid treated rheumatoid arthritis.

Authors:  J E Compston; S Vedi; P I Croucher; N J Garrahan; M M O'Sullivan
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

8.  Effect of calcitonin on bone histomorphometry and bone metabolism in rheumatoid arthritis.

Authors:  H Kröger; I Arnala; E M Alhava
Journal:  Calcif Tissue Int       Date:  1992-01       Impact factor: 4.333

9.  Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis.

Authors:  T D Spector; I T James; G M Hall; P W Thompson; D Perrett; D J Hart
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

Review 10.  Interaction of the endocrine system with inflammation: a function of energy and volume regulation.

Authors:  Rainer H Straub
Journal:  Arthritis Res Ther       Date:  2014-02-13       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.